Senate panel grants Drilon’s motion to publicize ITRs of persons, companies in Pharmally issue | Inquirer News

Senate panel grants Drilon’s motion to publicize ITRs of persons, companies in Pharmally issue

/ 03:07 PM October 28, 2021
Senate panel grants Drilon’s motion to publicize ITRs of persons, companies in Pharmally issue

Senate Minority Leader Franklin Drilon, during Thursday’s virtual hearing of the Blue Ribbon Committee, October 28, 2021 on the budget utilization of the Department of Health (DOH) on COVID-19-related programs. (Screengrab/Senate PRIB)

MANILA, Philippines — The Senate blue ribbon committee has granted the motion of Senate Minority Leader Franklin Drilon, to publicize the income tax return of individuals and companies involved in the anomalies concerning the Pharmally Pharmaceutical Corp.

During the committee’s hearing on Thursday, Drilon moved to release the income tax return (ITR) documents given to the Senate through an executive session, by way of the approval of the committee.


Senate rules state that documents and testimonies provided in an executive session cannot be released publicly unless the committee agrees to do so.

“It is in this context Mr. Chair that I move that the income tax returns which were provided by the BIR to the committee — which under the law should be given in an executive session — should be made public because of what we have learned so far,” Drilon said.


“Under our rules of procedure governing inquiries in aid of legislation, it provides that testimony taken or material presented in executive session shall not be made public in rule and part unless authorized by the committee,” he added.

According to Drilon, he was compelled to move for the publication of the ITRs after learning that several individuals and companies linked to Pharmally — from former presidential economic adviser Michael Yang who helped finance the company, and Greentrends Trading International Inc. and Xuzhou Construction Machinery Group, did not file any ITRs for several years.

He said that it also stemmed from Xuzhou’s admission in the past hearing that they have not paid any taxes.

“I discussed with the chairman, for the record, before the hearing, and this is our desire for the government to look into the taxes paid by these suppliers. And this is prompted Mr. Chairman by the revelation done by Xuzhou Construction Machinery,” Drilon said.

“Kung inyo pong maaalala noong nakaraang pagdidinig, ang kumpanyang Xuzhou […] inamin na hindi po sila nagbayad ng income taxes, ni piso po — magkano po ang kanilang kontrata? Dalawang bilyon, dalawampu’t tatlong milyon P2.230 billion ang kanilang kontrata na inaward no’ng panahon ng dating undersecretary Lloyd Christopher Lao,” he added.

In the same motion, Drilon said that the public should not forget that the root of the hearings was the Commission on Audit’s move to flag the Department of Health (DOH) transfer of its P42 billion funds to the Procurement Service of the Department of Budget and Management (PS-DBM).

Part of the funds, around P8.7 billion, were contracts given to Pharmally.


Drilon said that the government should ascertain if all the companies who got their share in the P42 billion worth of contracts fulfilled their tax obligations.

“It is in this context Mr. Chairman, with the permission of my colleagues, that I would ask that we look into the tax liabilities of these contractors. To put it in context: we should not forget that P42 billion was transferred by the Department of Health to PS-DBM which was flagged by the COA,” Drilon said.

“Ang tanong po, doon sa P42 billion na dinisburse ng PS-DBM sa mga suppliers, magkanong buwis ang binayad ng mga suppliers na ito,” he added.

The Senator said that this is important as President Rodrigo Duterte has insisted several times that the government is short of funds in its COVID-19 response. Proper tax collection, Drilon believes, would have provided the country with additional funding.

He said that around P7.5 billion worth of taxes should have been generated after the PS-DBM deals.

“Mr. Chairman, Mr. President Duterte is always telling the public that hirap na hirap ang pamahalaan, wala pong pangbayad kaya po ‘yong ayuda ay hindi po nabibigay. ‘Yon pong pambili ng bakuna, P45 billion eh nasa unprogrammed fund, ibig sabihin walang pondo doon sa P45 billion,” he noted.

“Ay hindi po ba tama lamang na tignan natin doon po sa magandang mga kontrata na nakuha ng lahat ng suppliers, magkano po ang binayad nilang income tax?” he asked.

In the same hearing, Drilon later showed that Yang, former PS-DBM head Lloyd Christopher Lao, and the companies mentioned have not filed their ITRs for several years.

Pharmally remains at the center of the Senate’s investigation on the deficiencies in the DOH’s COVID-19 funds amounting to P67.32 billion.

The committee is trying to identify why Pharmally, despite having a small paid-up capital of only P625,000, got a huge share of the contracts.

There are also accusations that Pharmally’s equipment was overpriced, like in the case of face masks sold at over P27 per piece in April 2020, when other companies offered a price of P13 per piece.

READ: P8.7-B med supply deals went to tiny company 

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Lloyd Christopher Lao, Michael Yang, overpriced goods, Pharmally Pharmaceutical Corp., Philippine news updates, Procurement Service of the Department of Budget and Management, PS-DBM, Senate, Senate blue ribbon committee, Senator Franklin Drilon
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.